Sun Dec 21 12:00:43 SGT 2014  
SINGAPORE
GENITAL™
    Genital warts treatment, Singapore (SG)
HIV STD TESTING SINGAPORE™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment
28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™

Summary

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™ @singaporegenital_com: Genital warts (condyloma, condylomata acuminata, venereal wart, anal wart, anogenital wart, "cauliflower" sex disease) screening/diagnosis, testing/check treatment/removal/cure, Singapore. Private and confidential service. Definitions, references, and latest news.

Description

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital warts treatment, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

School-Located Vaccination Clinics for Adolescents: Correlates of Acceptance Among Parents
Sat, 20 Dec 2014 22:12:35 +0100 | Journal of Community Health
This study seeks to determine the relationship between attitudes of parents of middle- and high-school students and acceptance of SLVCs for all four adolescent recommended vaccines. We conducted a telephone and web-based survey among parents of students enrolled in six middle and five high schools in Georgia. Analyses were conducted to examine associations between parental attitudes and willingness to allow their child to be vaccinated at school. Tdap and influenza vaccine had the highest rates of parental SLVC acceptance while HPV vaccine had the lowest. Parents who accepted SLVCs had higher perceived severity of influenza, meningococcal, and HPV illnesses compared to parents who did not accept SLVC. Intention to vaccinate was associated with SLVC acceptance for Tdap [Adjusted OR (AOR) 7....

Reliability of the Xpert HPV Assay to Detect High-Risk Human Papillomavirus DNA in a Colposcopy Referral Population.
Sat, 20 Dec 2014 07:45:13 +0100 | American Journal of Clinical Pathology
CONCLUSIONS: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Sat, 20 Dec 2014 00:00:00 +0100 | The Lancet
This study is registered with ClinicalTrials.gov, number NCT00294047. Findings The first participant was enrolled on Feb 16, 2006, and the last study visit for the present analysis took place on Dec 10, 2010; 5752 women were included in the total vaccinated cohort (n=2881 vaccine, n=2871 control), and 4505 in the according-to-protocol cohort for efficacy (n=2264 vaccine, n=2241 control). Vaccine efficacy against HPV 16/18-related 6-month persistent infection or CIN1+ was significant in all age groups combined (81·1%, 97·7% CI 52·1–94·0), in the 26–35 years age group (83·5%, 45·0–96·8), and in the 36–45 years age group (77·2%, 2·8–96·9); no cases were seen in women aged 46 years and older. Vaccine efficacy against atypical squamous cells of undetermined significance or ...

Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, Southeast China: a cross-sectional study
Fri, 19 Dec 2014 00:00:00 +0100 | BMC Infectious Diseases
Conclusions:

Relative Expression of Vascular Endothelial Growth Factor Isoforms in Squamous Cell Carcinoma of the Head and Neck
Thu, 18 Dec 2014 22:51:00 +0100 | Head and Neck
Conclusions: Differential VEGF isoform expression is not a reliable prognostic biomarker for either the clinically node negative/pathologically node positive neck or overall survival in pharyngeal and laryngeal SCCHNs. This article is protected by copyright. All rights reserved. (Source: Head and Neck)

Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease
Thu, 18 Dec 2014 14:22:13 +0100 | Transplantation
No abstract available (Source: Transplantation)

Anorectal Human Papillomavirus: Current Concepts.
Thu, 18 Dec 2014 09:43:55 +0100 | The Yale Journal of Biology and Medicine
Authors: Assi R, Reddy V, Einarsdottir H, Longo WE

GARDASIL (Human Papillomavirus Quadrivalent (Types 6, 11, 16, And 18) Vaccine, Recombinant) Injection, Suspension [REMEDYREPACK INC. ]
Thu, 18 Dec 2014 05:00:00 +0100 | DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)
Updated Date: Dec 18, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

EAU Guidelines on Penile Cancer: 2014 Update
Thu, 18 Dec 2014 00:00:00 +0100 | European Urology
Conclusions Organ preservation has become the standard approach to low-stage penile cancer, whereas in lymphatic disease, it is recognised that multimodal treatment with radical inguinal node surgery and adjuvant chemotherapy improves outcome. Patient summary Approximately 80% of penile cancer patients of all stages can be cured. With increasing experience in the management of penile cancer, it is recognized that organ-preserving treatment allows for better quality of life and sexual function and should be offered to all patients whenever feasible. Referral to centres with experience is recommended. Penile preservation should be offered as the primary treatment modality to men with localised penile cancer. Conservative surgery may improve quality of life; however, the risk of local recurr...

Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: A candidate molecule for therapeutic intervention and prognostic biomarker?
Thu, 18 Dec 2014 00:00:00 +0100 | Biochimica et Biophysica Acta (BBA) Reviews on Cancer
Publication date: December 2014 Source:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1846, Issue 2 Author(s): Fabrícia Gimenes , Jorge Juarez Vieira Teixeira , André Luelsdorf Pimenta de Abreu , Raquel Pantarotto Souza , Monalisa Wolski Pereira , Vânia Ramos Sela da Silva , Cinthia Gandolfi Bôer , Silvya Stuchi Maria-Engler , Marcelo Gialluisi Bonini , Sueli Donizete Borelli , Márcia Edilaine Lopes Consolaro While persistent infection with oncogenic types of human Papillomavirus (HPV) is required for cervical epithelial cell transformation and cervical carcinogenesis, HPV infection alone is not sufficient to induce tumorigenesis. Only a minor fraction of HPV infections produce high-grade lesions and cervical cancer, suggesting complex host–virus interactions. Bas...